Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alzamend Neuro, Inc.ALZN · Entity 8081 | Director · Chief Executive Officer | April 30, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alzamend Neuro, Inc.
Report date April 30, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2035-11-12 | Direct | 450,000 |
Reported balance
After 2026-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-17 · Grant · Acquired 450,000 · Balance 450,000 F1: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Jackman to purchase 450,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Jackman to purchase 450,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2026 Filed Aug 5, 2026 01:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantStock Options (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001214659-26-009586 · marketforms-73673.xml · derivative · entry 1 Jackman Stephan · CIK 0001864257 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-11-12 F1 · derivative.exercise_date: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Jackman to purchase 450,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026. Read SEC document |
| April 28, 2023 Filed May 2, 2023 20:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | PurchaseCommon Stock | 37,000 | $0.54 | $19,998.50 |
DisclosureSEC source: 0001214659-23-006373 · marketforms-61359.xml · nonDerivative · entry 1 Jackman Stephan · CIK 0001864257 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,500 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.5405. The range of purchase prices on the transaction date was $0.5398 to $0.5499 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantStock Option (Right to Buy) · Derivative | 2,000,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001214659-22-014319 · marketforms-57706.xml · derivative · entry 1 Jackman Stephan · CIK 0001864257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires 2032-11-28 F1 · derivative.exercise_date: On November 29, 2022, Mr. Jackman was granted options to purchase 2,000,000 shares of common stock of Alzamend Neuro, Inc. (the "Issuer"), of which (i) 50% would vest if the Issuer completed and announced topline data, within three years from the grant date, from a Phase II clinical trial of AL001 that would support a new drug application ("NDA") in Alzheimer's Disease and (ii) 50% would vest if the Issuer completed and announced topline data, within four years from the grant date, from a Phase II clinical trial of ALZN002 that would support an NDA in Alzheimer's Disease. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 20:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | PurchaseCommon Stock | 8,500 | $1.23 | $10,414.20 |
DisclosureSEC source: 0001214659-22-011325 · marketforms-57156.xml · nonDerivative · entry 1 Jackman Stephan · CIK 0001864257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.2252. The range of purchase prices on the transaction date was $1.225 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.